Halozyme Therapeutics Intrinsic Value Calculator – Halozyme Therapeutics Earnings Fall Short of Expectations
May 10, 2023
Trending News 🌥️
Unfortunately, the results fell short of expectations. Non-GAAP earnings per share (EPS) came in at $0.47, missing the mark by $0.01. Revenue of $162.14M was also lower than the predicted amount of $175.52M, coming in $13.38M short. Halozyme Therapeutics ($NASDAQ:HALO) is a leader in developing and commercializing patented drug delivery technologies designed to increase the efficiency of certain drugs. They have multiple therapies in clinical development and several approved products. Their proprietary technology is designed to facilitate the delivery of injectable drugs, including cancer treatments, into the body via subcutaneous injection instead of intravenous infusion.
In addition, they are focusing on developing new therapies for autoimmune diseases and neurological indications. Halozyme Therapeutics’ goal is to develop treatments that will provide improved outcomes for patients suffering from serious conditions.
Earnings
HALOZYME THERAPEUTICS recently released their earnings report for the fourth quarter of the fiscal year 2022, ending on December 31, 2022. The report showed that their total revenue was 181.5M USD while their net income was 57.7M USD. This marks a 77.9% increase in total revenue compared to the previous year’s earnings, but a 13.6% decrease in net income. Over the past three years, HALOZYME THERAPEUTICS has seen a significant increase in their total revenue as it has grown from 121.7M USD to 181.5M USD.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Halozyme Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 660.12 | 202.13 | 30.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Halozyme Therapeutics. More…
| Operations | Investing | Financing |
| 240.11 | -487 | 362.37 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Halozyme Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.84k | 1.67k | 1.26 |
Key Ratios Snapshot
Some of the financial key ratios for Halozyme Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 49.9% | 21.2% | 40.3% |
| FCF Margin | ROE | ROA |
| 35.6% | 124.6% | 9.0% |
Price History
On Tuesday, Halozyme Therapeutics reported earnings that fell short of expectations. When the markets opened, the company’s stock opened at $30.1, but closed at $30.6, up by only 1.0% from the previous day’s closing price of $30.3. This mild bump was insufficient to meet analysts’ estimates, resulting in a miss on the quarterly earnings report.
Halozyme Therapeutics had been enjoying relatively positive results in the past few quarters, so this earnings report was a surprise for many investors. As such, the stock’s market performance was relatively disappointing. Live Quote…
Analysis – Halozyme Therapeutics Intrinsic Value Calculator
At GoodWhale, we conducted an analysis of HALOZYME THERAPEUTICS‘s financials, and determined its intrinsic value to be around $65.7. This was calculated using our proprietary Valuation Line. Currently, HALOZYME THERAPEUTICS stock is trading at $30.6 – which is undervalued by 53.4%. This presents a great opportunity for investors who are looking to get a good return on their investments. More…
Peers
The Company’s enzyme-based product candidates target the tumor microenvironment, enabling the delivery of cancer drugs directly to the site of the tumor. Halozyme has four product candidates in clinical development, PEGPH20, Hylenex, HALO-102 and HALO-201. Keymed Biosciences Inc, Verona Pharma PLC, Xencor Inc are Halozyme’s competitors in the biopharmaceutical market.
– Keymed Biosciences Inc ($SEHK:02162)
Keymed Biosciences Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer and other serious diseases. The company’s market cap is 12.95B as of 2022 and has a ROE of -4.34%. Keymed Biosciences Inc’s products are designed to target key drivers of disease progression and to provide patients with new treatment options. The company’s lead product, KEY-184, is a first-in-class, orally-available small molecule inhibitor of the MDM2 oncoprotein.
– Verona Pharma PLC ($NASDAQ:VRNA)
Verona Pharma PLC is a pharmaceutical company that focuses on the development of drugs for the treatment of respiratory diseases. The company has a market cap of 790.27M as of 2022 and a Return on Equity of -28.69%. Verona Pharma PLC is headquartered in London, United Kingdom.
– Xencor Inc ($NASDAQ:XNCR)
Xencor Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company’s market cap as of 2022 is 1.64B with a ROE of 4.05%. Xencor is currently working on several clinical-stage programs including XmAb5871 for the treatment of B-cell malignancies, autoimmune diseases, and asthma.
Summary
Additionally, the company’s reported revenue of $162.14M was short of the projected $175.52M by $13.38M. This may be an indication of a potential slowdown in the company’s future performance. Investors should consider potential risks and analyze the company’s other financials to make informed decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
